Neurogene (NGNE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
Meeting called to order by the Executive Chair with board members, management, and external representatives present.
Inspector of Elections and Secretary roles assigned; meeting rules and agenda reviewed for orderly conduct.
Only stockholders of record as of April 7, 2026, were eligible to participate and vote.
Board and executive committee updates
Board members and senior management introduced, including Lead Independent Director and other directors.
Shareholder proposals
No shareholder proposals were submitted in accordance with advance notice bylaw provisions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Neurogene
- NGN-401 shows robust, durable efficacy and safety, advancing toward commercialization for Rett syndrome.NGNE
Corporate presentation - NGN-401 showed robust efficacy and safety, with cash runway into Q1 2029.NGNE
Q2 2026 - NGN-401's pivotal study nears completion, with 12-month data and US commercialization on track for 2026.NGNE
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - NGN-401 gene therapy enabled rapid, durable, multidomain gains with strong safety in Rett syndrome.NGNE
Study result - NGN-401 shows durable, multidomain benefits in Rett syndrome, with pivotal trial and launch prep underway.NGNE
Corporate presentation - NGN-401 Embolden trial dosing nears completion; strong cash runway and interim data expected mid-2026.NGNE
Q1 2026 - NGN-401 shows sustained, multi-domain gains in Rett syndrome with high responder rates and robust safety.NGNE
TD Cowen 46th Annual Health Care Conference - Board recommends approval of all proposals, with detailed governance and compensation disclosures.NGNE
Proxy filing - Key votes include director elections, executive pay, auditor ratification, and say-on-pay frequency.NGNE
Proxy filing